GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The company has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
Follow-Up Questions
Who is the CEO of Globeimmune Inc?
Dr. Timothy Rodell is the President of Globeimmune Inc, joining the firm since 2003.
What is the price performance of GBIM stock?
The current price of GBIM is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Globeimmune Inc?
Globeimmune Inc belongs to Biotechnology industry and the sector is Health Care
